Present and future in the treatment of chronic spontaneous urticaria

Close metadata

RELEVANCE

Chronic spontaneous urticaria (CSU) is a disease that affects 20% of patients for more than 5 years. Every fifth patient has tachyphylaxis and does not respond to traditional therapy. Problems of predicted side effects, the increasing growth of refractory cases on therapy, and the quality of life of patients are still decreasing. The review describes a modern view of the pathogenesis of CSU, approved treatment for this disease, as well as the possibility for the treatment of patients with chronic spontaneous urticaria.

OBJECTIVE

To study relevant methods of therapy for CSU.

GOAL

The review describes a modern view of the pathogenesis of CSU, approved treatment for this disease, as well as the possibility for the treatment of patients with chronic spontaneous urticaria.

MATERIALS AND METHODS

Searched PubMed databases, eLibrary data, CyberLeninka, ClinicalTrials.gov. for 2018–2020. The analysis included 80 publications (including original studies, case reports, literature reviews, and meta-analyzes). The modern views on the pathogenesis of CSU, methods of treatment of this disease, as well as its prospects in the treatment of patients with CSK are analyzed.

RESULTS

There are many different therapies nowadays. A widely discussed group of drugs are genetically engineered biological remedies. In our review, we describe about 63 drugs that are used in the treatment of either chronic spontaneous urticaria, or dermatoses similar in pathogenesis, or are under development drugs.

CONCLUSION

The pathogenesis of the disease determines the significant number of targeted drugs’ creation. At the same time, the mechanisms of CSU development are not fully understood. Further clinical studies are needed to investigate the efficacy and safety of drugs which are under development.

Keywords:

chronic urticaria

chronic spontaneous urticaria

genetically engineered biological drugs

omalizumab

Authors:

Pereverzina N.O.

Central state medical academy of department of presidential affairs

Kruglova L.S.

Central State Medical Academy of Department of Presidential Affairs

Scopus AuthorID: 24168854300
ORCID: 0000-0002-5044-5265

Musaev I.E.

Russian National Research Medical University named after N.I. Pirogov

Received:

25.02.2020

Accepted:

17.08.2020

List of references:

Zuberbier T, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018; 73(7):1393-1414.
Kocatürk E, et al. Looking forward to new targeted treatments for chronic spontaneous urticaria. Clinical and translational allergy. 2017;7(1):1.
Guillen-Aguinaga S, Jauregui Presa I, Aguinaga-Ontoso E, Guillen-Grima F, Ferrer M. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. The British journal of dermatology. 2016;175:1153-1165.
Asero R, Pinter E, Marra AM, et al. Current chal- lenges and controversies in the management of chronic spontaneous urticaria. Expert Rev Clin Immunol. 2015;11:1073-1082.
Silvares MRC, Fortes MR, Miot HA, et al. CSU and Angioedema. Rev Assoc Med Bras. 2011;57:577-582.
O’Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136:197-201.
Clinical Guidelines for treatment urticaria. Russian society of dermatologist and cosmetologist. 2016:31. (In Russ.).
Navinés-Ferrer A, et al. IgE-related chronic diseases and anti-IgE-based treatments. Journal of immunology research. 2016;4:1-12.
Pennington LF, et al. Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. Nature communications. 2016;7(1):1-12.
Zuberbier T, Bernstein JA. A comparison of the United States and international perspective on chronic urticaria guidelines. The Journal of Allergy and Clinical Immunology: In Practice. 2018;6(4):1144-1151.
Kocatürk E, Deza G, Kızıltaç K, Giménez-Arnau AM. Omalizumab Updosing for Better Disease Control in Chronic Spontaneous Urticaria Patients. International archives of allergy and immunology. 2018;177:360-364.
Kolkhir P, et al. New treatments for chronic urticaria. Annals of Allergy, Asthma & Immunology. 2019.
Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy. 2014;44:1371-1385.
Maurer M, et al. Ligelizumab for chronic spontaneous urticaria. New England Journal of Medicine. 2019;381(14):1321-1332.
Magerl M, Terhorst D, Metz M, et al. Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2018;16:477-478.
Maurer M, Altrichter S, Metz M, Zuberbier T, Church MK, Bergmann K-C. Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria. Journal of the European Academy of Dermatology and Venereology. 2018;32:112-113.
Bergmann KC, Altrichter S, Maurer M. Benefit of benralizumab treatment in a patient with chronic symptomatic dermographism. Journal of the European Academy of Dermatology and Venereology. 2019;33(11):413-415. Epub ahead of print.
Shirley M. Dupilumab: First Global Approval. Drugs. 2017;77:1115-1121.
Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2019;7:1659-1661. e1651.
Laurberg G. Tranexamic acid (Cyklokapron) in chronic urticaria: a double-blind study. Acta Derm Venereol. 1977;57:369-370.
Wilson LH, Eliason MJ, Leiferman KM, Hull CM, Powell DL. Treatment of refractory chronic urticaria with tumor necrosis factor-alfa inhibitors. Journal of the American Academy of Dermatology. 2011;64:1221-1222.
Kocatürk E, Zuberbier T. New biologics in the treatment of urticaria. Current opinion in allergy and clinical immunology. 2018;18(5):425-431.
Combalia A, Losno RA, Prieto-González S, Mascaró JM. Rituximab in Refractory Chronic Spontaneous Urticaria: An Encouraging Therapeutic Approach. Skin Pharmacology and Physiology. 2018;31:184-187.
Krause K, Mahamed A, Weller K, Metz M, Zuberbier T, Maurer M. Efficacy and safety of canakinumab in urticarial vasculitis: An open-label study. Journal of Allergy and Clinical Immunology. 2013;132:751-754.e755.
Lenormand C, Lipsker D. Efficiency of interleukin-1 blockade in refractory delayed-pressure urticaria. Ann Intern Med. 2012;157:599-600.
Bodar EJ, Simon A, de Visser M, van der Meer JW. Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra). Neth J Med. 2009;67:302-305.
Huang X, Li Z, Sun R. High-dose levocetirizine for the treatment of refractory chronic spontaneous urticaria and the effect on the serum inositol triphosphate level. Journal of International Medical Research. 2019;47(9):4374-4379.
Ramirez Molina C et al. GSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex vivo human skin. British journal of pharmacology. 2019;176(8):1135-1142.
Corren J, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Rα antagonist, in patients with asthma. American journal of respiratory and critical care medicine. 2010;181(8):788-796.
Handbook of Therapeutic Antibodies, Volume 4. Front Cover. Stefan D¿bel, Janice M. Reichert. John Wiley & Sons. 2014;2544.
Kalamaha K, et al. Atopic dermatitis: a review of evolving targeted therapies. Expert review of clinical immunology. 2019;15(3):275-288.
Boyman O, Kaegi C, Akdis M, Bavbek S, Bossios A, Chatzipetrou A, Eiwegger T, Firinu D, Harr T, Knol E, Matucci A, Palomares O, Schmidt-Weber C, Simon HU, Steiner UC, Vultaggio A, Akdis CA, Spertini F. EAACI IG biologicals task force paper on the use of biologic agents in allergic disorders. Allergy. 2015;70(7):727-754.
Khattri S, et al. Efficacy and safety of ustekinumab treatment in adults with moderate‐to‐severe atopic dermatitis. Experimental dermatology. 2017; 26(1):28-35.
Shroff A, Guttman-Yassky E. Successful use of ustekinumab therapy in refractory severe atopic dermatitis. JAAD case reports. 2015;1(1):25.
Renert-Yuval Y, Guttman-Yassky E. What’s new in atopic dermatitis. Dermatologic clinics. 2019;37(2):205-213.
Gauvreau GM, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. New England Journal of Medicine. 2014;370(22):2102-2110.
Smith SG, et al. Eculizumab for treatment of asthma. Expert opinion on biological therapy. 2012;12(4):529-537.
Krause K, et al. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. Journal of Allergy and Clinical Immunology. 2012; 129(3):848.
Makol A, Gibson LE, Michet CJ. Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis. J Clin Rheumatol. 2012;18:92-95.
Deza G, et al. Emerging biomarkers and therapeutic pipelines for chronic spontaneous urticaria. The Journal of Allergy and Clinical Immunology: In Practice. 2018;6(4):1108-1117.
Harris JM, Cabanski CR, Scheerens H,et al. A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria. J Allergy Clin Immunol. 2016;138:1730-1732.
Verstovsek S, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. New England Journal of Medicine. 2010;363(12): 1117-1127.
Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76:736-744.
Yacoub A, Prochaska L. Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis. Biomark Res. 2016;4:2.
Fukunaga A, Ito M, Nihigori C. Efficacy of Oral Ruxolitinib in a Patient with Refractory Chronic Spontaneous Urticaria. Acta dermato-venereologica. 2018;98(9-10):904-905.
Caproni M, Volpi W, Giomi B, Torchia D, Del Bianco E, Fabbri P. Cellular adhesion molecules in chronic urticaria: modulation of serum levels occurs during levocetirizine treatment. Br J Dermatol. 2006;155(6):1270-1274.
Haas N, Henz BM, Hermes B. Adhesion molecules and cellular infiltrate: histology of urticaria. Journal of Investigative Dermatology Symposium Proceedings. Elsevier, 2001;6(2):137-138.
Zuberbier T, et al. Enhanced P-selectin expression in chronic and dermographic urticaria. International archives of allergy and immunology. 1997; 114(1):86-89.
Barlow RJ, et al. Adhesion molecule expression and the inflammatory cell infiltrate in delayed pressure urticaria. British Journal of Dermatology. 1994; 131(3):341-347.
Shmidt TE. Natalizumab in the treatment of remitting multiple sclerosis. Neurological Journal. 2014;19(3):57-61. (In Russ.).
Nyborg AC, et al. Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells. Cellular & molecular immunology. 2016;13(3):391-400.
Fujisawa D, et al. Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. Journal of allergy and clinical immunology. 2014;134(3):622-633. e9.

Close metadata